TEAM
STÉPHANE PYRONNET & FABIENNE MEGGETTO

THE SPECIFICITIES
OF OUR RESEARCH AXIS

Post-transcriptional events involving RNAs allow for rapid control of gene expression at low energy cost to the cell. They are particularly solicited when cells are subjected to a stressed environment, as in a malignant tumor or under the effect of anti-tumor treatments. They can then contribute to the adaptation processes necessary for malignant transformation and/or resistance to treatments.

In a clinical perspective, using combined approaches of new generation and high throughput RNA sequencing (“bulk” or “single-cell RNAseq”) and cellular and tissue imaging, our team explores the whole RNA repertoire (coding mRNAs and non-coding regulatory RNAs including miRNAs, lncRNAs and circRNAs) and its heterogeneity within the tumor, in cohorts of patients with hematological tumors (acute myeloid leukemias and pediatric T lymphomas). The objective is the identification of new therapeutic and/or sensitizing targets.

 On a cognitive and mechanistic level, the team then implements molecular (gain/loss of function), cellular and in vivo (genetic models and human tumor avatars or PDXs) experimental approaches for characterizing the new potential targets functionally and for deciphering their mechanisms of action. In partnership with industrialists, the possibility of targeting them with molecules offering a therapeutic potential is also explored.

RESEARCH PROJETCS

Participate

SCIENTIFIc PRODUCTIONS

Envie de rejoindre
L’équipe du CRCT ?